Lisdexamfetamine (Vyvanse, Takeda Pharmaceuticals) has shown early success in the reduction of sluggish cognitive tempo for 38 patients with attention-deficit hyperactivity disorder (ADHD), according to the results of a study published in the Journal of Clinical Psychiatry. It is currently debated whether or not sluggish cognitive tempo—defined as a collection of symptoms that include persistent dreaminess, fatigue, and slow working speed—is part of ADHD or separate from it.